Eric Groen - Rani Therapeutics General Counsel
| RANI Stock | USD 2.02 0.03 1.51% |
Executive
Eric Groen is General Counsel of Rani Therapeutics Holdings
| Age | 53 |
| Address | 2051 Ringwood Avenue, San Jose, CA, United States, 95131 |
| Phone | 408 457 3700 |
| Web | https://www.ranitherapeutics.com |
Eric Groen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eric Groen against Rani Therapeutics stock is an integral part of due diligence when investing in Rani Therapeutics. Eric Groen insider activity provides valuable insight into whether Rani Therapeutics is net buyers or sellers over its current business cycle. Note, Rani Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Rani Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eric Groen over six months ago Disposition of 43400 shares by Eric Groen of Rani Therapeutics at 13.21 subject to Rule 16b-3 |
Rani Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5683) % which means that it has lost $0.5683 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2535) %, meaning that it created substantial loss on money invested by shareholders. Rani Therapeutics' management efficiency ratios could be used to measure how well Rani Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.62. The current Return On Capital Employed is estimated to decrease to -1.39. As of now, Rani Therapeutics' Fixed Asset Turnover is increasing as compared to previous years. The Rani Therapeutics' current Asset Turnover is estimated to increase to 0.03, while Non Current Assets Total are projected to decrease to under 6.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Qing Yuan | Cabaletta Bio | 53 | |
| Ray Knox | Lyra Therapeutics | N/A | |
| Alan Fuhrman | Tyra Biosciences | 67 | |
| Robert MD | Lyra Therapeutics | N/A | |
| Jill CPA | Vaccinex | 52 | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Athanasios MD | Alx Oncology Holdings | N/A | |
| Esther Jhun | Surrozen | N/A | |
| MD MBA | Molecular Partners AG | N/A | |
| Cheryl Madsen | Viracta Therapeutics | N/A | |
| Alan CPA | Tyra Biosciences | 67 | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Katie McManus | Trevi Therapeutics | N/A | |
| Justine OMalley | Protara Therapeutics | N/A | |
| Karen MBA | Vincerx Pharma | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| David MA | Eyepoint Pharmaceuticals | 57 | |
| Allison Dillon | Alx Oncology Holdings | N/A | |
| Timothy Hoey | Tenaya Therapeutics | 65 | |
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Ravi Upasani | Biomea Fusion | N/A | |
Management Performance
| Return On Equity | -2.25 | ||||
| Return On Asset | -0.57 |
Rani Therapeutics Leadership Team
Elected by the shareholders, the Rani Therapeutics' board of directors comprises two types of representatives: Rani Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rani. The board's role is to monitor Rani Therapeutics' management team and ensure that shareholders' interests are well served. Rani Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rani Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alireza Javadi, Vice Operations | ||
| Svai Sanford, Chief Officer | ||
| Mir Hashim, Chief Officer | ||
| Arvinder Dhalla, Vice Development | ||
| Bella Vazquez, Vice Resources | ||
| Eric Groen, General Counsel | ||
| Kate MBA, Chief Officer | ||
| Talat Imran, CEO Director | ||
| Mir Imran, Executive Chairman |
Rani Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rani Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.25 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 69.62 M | ||||
| Shares Outstanding | 33.31 M | ||||
| Shares Owned By Insiders | 30.61 % | ||||
| Shares Owned By Institutions | 19.58 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Book | 21.25 X | ||||
| Price To Sales | 313.17 X | ||||
| Gross Profit | 2.72 M |
Currently Active Assets on Macroaxis
When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.57) | Return On Equity (2.25) |
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.